Advanced Accelerator Applications — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Advanced Accelerator Applications appears in 16 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials16

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

16 shown

[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)NCT03724253 · lead sponsor · 2018-07-03

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate CancerNCT03490838 · lead sponsor · 2018-05-24

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)NCT03490032 · lead sponsor · 2018-05-23

99mTc-rhAnnexin V-128 in Diagnosis of SpondyloarthritisNCT03232580 · lead sponsor · 2017-09-18

99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerNCT02677714 · lead sponsor · 2016-11-02

99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)NCT02328027 · lead sponsor · 2014-12-11

177Lu-PSMA-617 Managed Access Program for mCRPC PatientsNCT04825652 · lead sponsor

NO_LONGER_AVAILABLE

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast CancerNCT04529044 · collaborator · 2026-06-30

Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)NCT05885009 · collaborator · 2023-03-28

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate CancerNCT06388369 · collaborator · 2025-08-25

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCNCT05150236 · collaborator · 2022-04-29

EBRT + Lu-PSMA for N1M0 Prostate CancerNCT05162573 · collaborator · 2021-12-20

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate CancerNCT04443062 · collaborator · 2020-07-20

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to ChemotherapyNCT04343885 · collaborator · 2020-04-21

ACTIVE_NOT_RECRUITING

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung CancerNCT03325816 · collaborator · 2017-11-20

F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate CancerNCT00963755 · collaborator · 2009-08-01

Sponsor roles

collaborator9

lead sponsor7

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.